midodrine has been researched along with Autonomic Failure, Pure in 1 studies
Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.
midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ramirez, CE | 1 |
| Okamoto, LE | 1 |
| Arnold, AC | 1 |
| Gamboa, A | 1 |
| Diedrich, A | 1 |
| Choi, L | 1 |
| Raj, SR | 1 |
| Robertson, D | 1 |
| Biaggioni, I | 1 |
| Shibao, CA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Midodrine and Atomoxetine Treatment in Patients With Neurogenic Orthostatic Hypotension : A Prospective Randomized Study[NCT03350659] | Phase 4 | 50 participants (Actual) | Interventional | 2018-01-01 | Completed | ||
| Phase 2 Norepinephrine Transporter Blockade, Autonomic Failure IND117394 12/28/12[NCT02784535] | Phase 2 | 48 participants (Actual) | Interventional | 2016-08-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
HR is compared to baseline after 10 mins of standing. The difference increase in Heart rate from baseline, post drug at 4 weeks (NCT02784535)
Timeframe: Baseline and at 4 weeks
| Intervention | Beats per minute (Mean) |
|---|---|
| Placebo | 79.12 |
| Atomoxetine | 82.68 |
Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) (measured in mm of Hg) , is recorded after 10 mins of standing. The changes SBP and DBP are compared from baseline, post drug (4 weeks) (NCT02784535)
Timeframe: Baseline to 4 weeks
| Intervention | mm of Hg (Mean) | |
|---|---|---|
| difference increase in SBP; post drug 4 weeks; standing for 10 mins | DBP;post drug; standing 10 mins at 4 weeks | |
| Atomoxetine | -2.44 | -0.94 |
| Placebo | 3.88 | -3.06 |
"The Orthostatic Hypotension Questionnaire (OHQ) , patient-reported assessment tool consisting of the OH Symptom Assessment (OHSA), OH Daily Activity Scale (OHDAS).~The composite score is composed of 10 individual items: 6 items measure specific symptoms , the Orthostatic Hypotension Symptom Assessment (OHSA), and 4 items measure the impact of those symptoms on a patient daily activities, the Orthostatic Hypotension Daily Activity Scale (OHDAS). This scales helps to measure the impact of orthostatic symptoms on daily.~Scale is between 0-10: where 0 is minimum Orthostatic symptoms and 10 is the maximum / worse possible severity of the symptoms.~All items are scored 0 through 10 (higher scores = more impact) and summed into the respective total scores.~The OHSA and OHDAS subscales averaged to compute the OHQ composite score." (NCT02784535)
Timeframe: week 0 to week 4
| Intervention | Score on a scale (Mean) | ||
|---|---|---|---|
| OHQ composite score at Baseline | OHQ composite score at 4weeks | Difference in OHQ composite score at 4 weeks | |
| Atomoxetin | 4.17 | 3.5 | -0.5 |
| Placebo | 4.61 | 3.35 | -0.58 |
1 trial available for midodrine and Autonomic Failure, Pure
| Article | Year |
|---|---|
Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure.
Topics: Administration, Oral; Adrenergic alpha-1 Receptor Agonists; Adrenergic Uptake Inhibitors; Aged; Atom | 2014 |
Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure.
Topics: Administration, Oral; Adrenergic alpha-1 Receptor Agonists; Adrenergic Uptake Inhibitors; Aged; Atom | 2014 |
Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure.
Topics: Administration, Oral; Adrenergic alpha-1 Receptor Agonists; Adrenergic Uptake Inhibitors; Aged; Atom | 2014 |
Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure.
Topics: Administration, Oral; Adrenergic alpha-1 Receptor Agonists; Adrenergic Uptake Inhibitors; Aged; Atom | 2014 |